Official Title Mechanisms of Self and Other Evaluation (MeSO Study)

Purpose

The purpose of this study is to better understand the way the brain works in people who have depression and people who have previously been depressed. We are also testing healthy subjects for comparison. We hope our findings will lead to better ways to diagnose and treat mood disorders in the future. Participation involves an initial phone call and a 2 to 4 hour visit to find out if you are eligible. This visit will include completing questionnaires and interviews. If eligible, participants will have a second 3-5 hour visit for an MRI scan. Two months after the scan, participants will complete daily online questionnaires for 7 days. This process is repeated 2 months later (4 months after the scan). 

Could this study be right for you?

You may be eligible for this study if you:

• Are between the ages of 18-40
• Are right-handed
• Do not have a history of neurological disorders (e.g., seizures, head injury, etc.)
• Do not have major medical problems (e.g., stroke, heart disease, high blood pressure, endocrine disorders, etc.)
• Have normal vision, vision that is corrected to normal with glasses or contacts
• Are willing and able to undergo fMRI scanning (not claustrophobic, no non-removable metal in your body)
• Are not pregnant

Age Range

18 and up

Official Title Mechanisms of Negative Affectivity

Purpose

Symptoms related to depression and anxiety can affect a person’s daily life and relationships. Some research suggests that people with mood and anxiety disorders process information differently than people without these types of disorders.

The purpose of this study is to better understand the way the brain works in people who have depression and anxiety. Researchers hope their findings will lead to better ways to diagnose and treat mood and anxiety disorders in the future.

Participation involves an initial phone call and a 3 to 5 hour visit to find out if you are eligible. This visit will include completing questionnaires and interviews. If eligible, participants will have a second 3-5 hour visit for an MRI scan.

The 3rd and 4th visits (at 6 and 12 months) will include 1.5 to 3 hours of questionnaires and interviews each.

Following the scan, the 6-month follow-up, and the 12-month follow-up, participants will also complete daily online questionnaires for 7 days.

Could this study be right for you?

You may be eligible for this study if you are:

• 18-25 years of age
• Right-handed
• Currently experiencing symptoms of depression or anxiety (feeling down or depressed, anxious, nervous, or tense, having no interest in things you used to enjoy, or feeling hopeless)
• Not currently receiving treatment (psychiatric medications or therapy)
• No major medical problems (e.g., stroke, heart disease, high blood pressure, endocrine disorders, etc.)
• No history of neurological disorders (e.g., seizures, head injury, etc.)
• Normal vision, vision that is corrected to normal with glasses or contacts
• Willing and able to undergo fMRI scanning (not claustrophobic, no non-removable metal in your body)
• Not pregnant

Participation involves an initial phone call and a 3 to 5 hour visit to find out if you are eligible. This visit will include completing questionnaires and interviews. If eligible, participants will have a second 3-5 hour visit for an MRI scan.

The 3rd and 4th visits (at 6 and 12 months) will include 1.5 to 3 hours of questionnaires and interviews each.

Following the scan, the 6-month follow-up, and the 12-month follow-up, participants will also complete daily online questionnaires for 7 days.

Age Range

18 and up

Official Title A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in people with Depression

Purpose

The purpose of this study is to see if a new drug (BI 1358894), taken in addition to a current antidepressant, is useful and safe for treating patients with Major Depressive Disorder.

You will be in this study approximately 13 weeks and have about 8 visits to the study center. You will also have about 2 visits that will be done by phone.

Could this study be right for you?

Inclusion Criteria:

• Between the ages of 18 and 65
• Currently taking an antidepressant
• Currently experiencing symptoms of depression

Age Range

18 and up

Official Title Parental History of Suicidal Behavior and Early Markers of Risk in Pre-pubescent Youth

Purpose

The purpose of this study is to learn what factors may be related to suicide attempt(s) in children (ages 6 - 9) that have a parental history of suicidal behavior in hopes that this information will help prevent and treat self-harm behavior in youth at high risk.

Both parents and children will complete questionnaires, interview questions, and a family discussion in addition to problem solving tasks and computer games.

There are multiple study visits. The first will last about 2.5 to 3 hours and all other appointments will occur annually from your first appointment. Due to COVID-19, families will have the option to conduct annual follow-up appointments via telephone. These annual telephone visits will last approximately 30-45 minutes. If the annual visit is conducted in-person, it will last 1.5 to 2.5 hours.

Could this study be right for you?

• Parents and children must be able to read and understand English fluently
• Child is 6 to 9 years of age
• Meet other criteria (e.g., no traumatic brain injury) for the study

Age Range

6 and up

Official Title A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults with Major Depressive Disorder

Purpose

Brexpiprazole is a medication being studied as a possible treatment for adjunctive treatment for Major Depressive Disorder (MDD). The reason for this study is to find out about the potential benefits and safety of Brexpiprazole.

Could this study be right for you?

Inclusion criteria:

• Between the ages of 18 and 65
• Currently depressed
• Currently taking an antidepressant
• Have tried at least 2 antidepressant medications

Age Range

18 and up

Official Title A Double-Blind, Placebo-Controlled Study of Cariprazine as an Adjunct to Antidepressants in the Treatment of Patients with Major Depressive Disorder Who Have had an Inadequate Response to Antidepressants Alone

Purpose

The purpose of this study is to look into the safety and efficacy of cariprazine as an add-on medication in the treatment of major depressive disorder.

Could this study be right for you?

Inclusion criteria:

• Between the ages of 18 and 61
• Currently taking an antidepressant
• Currently experiencing symptoms of depression

Age Range

18 and up

Official Title Decision-Making Abilities and Testamentary Capacity Among Older Adults

Purpose

The overall goal of this research is to examine factors such as social resources, personality characteristics, and neurocognitive functioning in relation to decision-making abilities testamentary capacity among healthy older adults.

Another purpose of this research study is to evaluate the impact of Problem-Solving Treatment-Primary Care (PST-PC), a cognitive-behavioral therapeutic approach, on decision making among healthy older adults. PST-PC involves a seven-step model, in which participants identify problems to be solved, discuss and evaluate different resolutions to reach desired goals; create action plans to accomplish determined goals; and evaluate their effectiveness in resolving designated problems.

We will compare the effectiveness of PST-PC on individuals who will not receive any intervention.

A no treatment control group of older adult participants will also be recruited to compare the effectiveness of PST-PC to individuals who do not receive the intervention. This no treatment control group will composed of participants who do not receive the PST-PC sessions.

Could this study be right for you?

Inclusion Criteria:

• adults aged 65 and older
• Must be independently-living and community-dwelling
• Participants must be willing to undergo a health interview to rule out outstanding medical and psychiatric conditions
• Adequate sensory abilities

Exclusion Criteria:

• A history of psychiatric illness necessitating inpatient treatment
• Participants with self-reported depression and/or anxiety exceeding mild levels of clinical severity

Age Range

65 and up

Official Title Mindfulness-based cognitive therapy for comorbid depression and type 2 diabetes

Purpose

The aim of this study is to improve mood and diabetes-related outcomes for those with type 2 diabetes mellitus (T2DM) AND symptoms of depression. The present study will examine the effect of mindfulness-based cognitive therapy (MBCT) on symptoms of depression and diabetes.

Your participation in this study will last 8 weeks.

Could this study be right for you?

You may qualify if:

• You are between the ages 18-75
• You have type 2 diabetes
• You are feeling symptoms of depression

Age Range

18 and up

Official Title A Double-blind, Placebo- and Active-controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Pediatric Patients 7-17 Years With Major Depressive Disorder

Purpose

The purpose of this research study is to evaluate the drug Levomilnacipran extended-release to see how well the drug works, observe the side effects, and how well tolerated it is compared to placebo in pediatric patients with major depressive disorder.

Could this study be right for you?

Your child may be eligible if:

• be between 7 and 17 years of age
• give their assent (a simplified version of this consent form that your child will sign)
• have a diagnosis of Major Depressive Disorder
• meet all of the additional relevant inclusion criteria
• understand the study instructions, and be willing and able to follow these instructions

Exclusion Criteria:

• Your child will not be able to take part in the study if she is pregnant, nursing, or planning a pregnancy
• Your child will not be able to take part in this study if he/she takes any illegal substances

Age Range

7 and up

Official Title A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-547 Injection in the Treatment of Adult Female Subjects with Severe or Moderate Post-partum Depression

Purpose

The purpose of this study is to evaluate the safety and effectiveness of an investigational medication in women with moderate to severe postpartum depression. The investigational medication is called SAGE-547 (allopregnanolone) . An investigational medication is one that is not yet approved by the United States Food and Drug Administration (FDA).

Could this study be right for you?

• Ages 18-45
• Currently depressed
• Less than 6 months postpartum

We will ask you to complete 4 study visits, including a Screening visit, a 3-day and night stay at the study center, and 2 follow-up visits.

Age Range

18 and up